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ABSTRACT
Vaccine-based autoimmune (anti-amyloid) treatments are
currently being examined for their therapeutic potential in
Alzheimer’s disease. In the present study we examined, in a
transgenic model of amyloid pathology, the expression of two
molecules previously implicated in decreasing the severity of
autoimmune responses: TREM2 (triggering receptor expressed
on myeloid cells 2) and the intracellular tolerance-associated
transcript, Tmem176b (transmembrane domain protein 176b).
In situ hybridization analysis revealed that both molecules
were highly expressed in plaque-associated microglia, but their
expression defined two different zones of plaque-associated
activation. Tmem176b expression was highest in the inner zone
of amyloid plaques, whereas TREM2 expression was highest in
the outer zone. Induced expression of TREM2 occurred co-
incident with detection of thioflavine-S-positive amyloid
deposits. Transfection studies revealed that expression of
TREM2 correlated negatively with motility, but correlated
positively with the ability of microglia to stimulate CD4
+ T-cell
proliferation, TNF (tumour necrosis factor) and CCL2 (chemo-
kine ligand 2) production, but not IFNc (interferon c)
production. TREM2 expression also showed a positive
correlation with amyloid phagocytosis in unactivated cells.
However, activating cells with LPS (lipopolysaccharide), but not
IFNc, reduced the correlation between TREM2 expression and
phagocytosis. Transfection of Tmem176b into both microglial
and macrophage cell lines increased apoptosis. Taken together,
these data suggest that, in vivo, Tmem176b
+ cells in closest
apposition to amyloid may be the least able to clear amyloid.
Conversely, the phagocytic TREM2
+ microglia on the plaque
outer zones are positioned to capture and present self-antigens
to CNS (central nervous system)-infiltrating lymphocytes with-
out promoting pro-inflammatory lymphocyte responses.
Instead, plaque-associatedTREM2
+microgliahavethepotential
to evoke neuroprotective immune responses that may serve to
support CNS function during pro-inflammatory anti-amyloid
immune therapies.
Key words: antigen presentation, autoimmunity, Clast1,
neuroinflammation, Torid.
INTRODUCTION
Microglia are the resident tissue macrophage of the CNS
(central nervous system) (Carson et al., 2007; Graeber and
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asnneuro.org / Volume 2 (3) / art:e00037 157Streit, 2010). Their activation is now a well-recognized feature
of Alzheimer’s disease in humans and amyloid pathogenesis in
transgenic animal models (Schwab et al., 2009; Cameron and
Landreth, 2010; Graeber and Streit, 2010). However, the net
beneficial compared with detrimental consequences of micro-
glial activation during amyloid pathogenesis is still unclear. In
part, the inability to resolve this debate is due to the highly
plastic phenotype of microglia.
Like all macrophages, CNS-resident microglia are able to
acquire a broad array of both cytotoxic and cytoprotective
functional states (Carson et al., 2007; Graeber and Streit,
2010). Perhaps most relevant to Alzheimer’s disease, microglia
can be activated to produce pro-inflammatory cytokines and
ROS (reactive oxygen species), as well as to phagocytose cell
debris, amyloid and produce neuroprotective growth factors
(Ziv et al., 2006; Butovsky et al., 2007; Takahashi et al., 2007;
Schwab et al., 2009; Cameron and Landreth, 2010). In
addition, microglia can differentiate into antigen-presenting
cells able to direct T-cell proliferation and activation (Carson
et al., 2006). Multiple in vivo and in vitro studies have
demonstrated that microglia are relatively inefficient in
driving pro-inflammatory CD4
+ T-cell responses as compared
with mature dendritic cells or even with other macrophage
populations (reviewed in Carson et al., 2006). Thus studies
focused on harnessing T-cell-driven anti-amyloid therapies
for Alzheimer’s disease have for the most part ignored
whether microglia have the potential to regulate anti-
amyloid T-cell responses and whether amyloid pathogenesis
alters microglial antigen-presenting cell function (Webster
et al., 2001; Monsonego and Weiner, 2003; Lemere et al.,
2006; Wilcock and Colton, 2009; Cameron and Landreth,
2010; Graeber and Streit, 2010).
Previousstudiesnowillustratethatmicrogliacanplayphysio-
logically significant roles as antigen-presenting cells that are
distinct from the roles played by peripheral ‘professional’
antigen-presenting cells (Byram et al., 2004; Carson et al.,
2006). For example, neuroprotective CD4
+ T-cell responses have
been shown tolower the rate of neuronal cell death in the facial
motoneuron nucleus following facial axotomy (Serpe et al.,
1999; Jones et al., 2005). Consistent with other models of CNS
autoimmunity, peripheral immune cells outside the CNS were
absolutely required to initiate CD4
+ T-cell responses following
facial axotomy (Hickey and Kimura, 1988; Byram et al., 2004;
Greter et al., 2005). Conversely, while microglia were unable to
initiate these T-cell responses, development of neuroprotective
T-cell function was absolutely dependent on subsequent
antigen-presentation by microglia within the injured CNS
(Byram et al., 2004).
The acquisition of specific microglial phenotypes is a
consequence of multiple regulatory inputs provided by inter-
actions with neurons, glia and CNS-infiltrating immune cells
(Carson et al., 2007; Tian et al., 2009). For example, healthy
neurons express ligands for inhibitory receptors such as CD200
receptor, CX3CR1 and CD45 (Mott et al., 2004; Cardona et al.,
2006; Koning et al., 2009). Damaged and/or dying neurons also
express and/or release molecules recognized by a wide array
microglial-expressed receptors specific for DAMPs (danger-
associated molecular patterns). For example, DAMP receptors
recognize the presence of free ATP, phosphatidylserine on
the external plasma membrane and expression of heat-shock
proteins (Grommes et al., 2008; Stefano et al., 2009; Clark
et al.,2010; Skaper etal.,2010; Toulme et al., 2010). Thus thenet
microglial response to any specific tissue damage and/or
pathogen is determined by the summation of all of their local
environmental cues. Regulation by summated environmental
cues suggests that microglial activation can be heterogeneous
and localized if activation/inhibition signals are also localized in
their availability. Indeed, many studies have defined region-
specific responses of microglia to inflammatory stimuli
(Melchior et al., 2006).
Microglial heterogeneity can also precede pathology.
Simply as a function of normal development and aging, the
expression of TREM2 (triggering receptor expressed on
myeloid cells 2) becomes increasingly heterogeneous
(Schmid et al., 2002; Carson et al., 2006; Schmid et al.,
2009; Thrash et al., 2009). Early in post-natal development all
microglia express similar levels of TREM2 that are readily
detected by in situ hybridization analysis (Thrash et al., 2009).
By young adulthood, only subsets of microglia expressed
levels of TREM2 that were readily detectable by in situ
hybridization (Schmid et al., 2002; Carson et al., 2006).
Notably, the highest levels of TREM2 expression per microglia
and the greatest percentage of TREM2 expression were found
in brain regions that develop amyloid pathology in human
Alzheimer’s disease and in transgenic models of amyloid
pathology (Schmid et al., 2002, Carson et al., 2006). Although
the disease mechanism is unknown, humans lacking a
functional TREM2 pathway develop early-onset cognitive
dementia that is apparent by the third decade of life and
which is distinct from Alzheimer’s disease-associated demen-
tia (Bianchin et al., 2004; Klu ¨nemann et al., 2005; Montalbetti
et al., 2005; Chouery et al., 2008).
In our present study, we focus on the role of TREM2 as
modulating microglial function in amyloid pathology for
two reasons. First, although TREM2 expression is not unique
to microglia, TREM2 is enriched ,10-fold in microglia as
compared with macrophages that acutely infiltrate the
CNS (Schmid et al., 2009). Furthermore, Frank et al. (2008)
reported TREM2 expression in plaque-associated microglia in
aged amyloid transgenic mice. Secondly, functional studies
suggest that TREM2 is primarily an anti-inflammatory receptor
associatedwithrepairmechanisms. AlthoughTREM2-mediated
activation of macrophages increases nitric oxide production, it
also promotes phagocytosis of apopotic cell debris and select
subsets of pathogens (Takahashi et al., 2005; Hsieh et al., 2009;
N9Diaye et al., 2009). TREM2 KO (knockout) mice reveal that
TREM2 functions to attenuate macrophage production of pro-
inflammatory cytokines in response to pro-inflammatory
stimulation (Takahashi et al., 2005; Hamerman et al., 2006;
Turnbull et al., 2006; Neumann and Takahashi, 2007; Takahashi
et al., 2007). In a model of colonic mucosal injury, macrophage
expression of TREM2 was required to promote complete and
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specific relevance to CNS disease, overexpressing TREM2 in
peripheral antigen-presenting cells did decrease the severity
and speeded the recovery from EAE (experimentally induced
autoimmune encephalomyelitis) (Takahashi et al., 2007).
Conversely, blocking TREM2 activity increased the severity of
EAE (Piccio et al., 2007).
Influx of macrophages into the CNS is also implicated in play-
ing roles in amyloid pathogenesis. We have previously reported
that in a spontaneously resolving LPS (lipopolysaccharide)-
induced model of CNS neuroinflammation, macrophages
infiltrating the CNS are induced to express similar levels of
the intracellular tetraspan molecule, called Tmem176b (trans-
membrane domain protein 176b) as expressed by CNS-resident
microglia (Schmid et al., 2009). As yet, little is known con-
cerning Tmem176b expression and function. However, Louvet
etal.(2005)havedemonstrated thattransfectionofTmem176b
into immature dendritic cells prevents activation-induced in-
creases in MHC class II, co-stimulatory molecules and cytokines
required for pro-inflammatory activation of CD4
+ T-cells. In
addition, increased Tmem176b expression was found to
correlate with increased allograft acceptance in a rat cardiac
transplant model (Louvet et al., 2005). Based on their data,
Louvet and colleagues termed this molecule Torid (tolerance-
related and induced transcript). In the present study, we have
chosen to use the NCBI unigene designation, Tmem176b, for
this molecule. Taken together the published data suggest that
Tmem176b may function to limit pro-inflammatory T-cell
responses and/or to promote resolution of pro-inflammatory
T-cell responses.
In our present study, we find that both TREM2 and
Tmem176b are induced co-incident with amyloid plaque
development in APP23 transgenic mice. Our in vitro assays
suggest that, in vivo, amyloid-induced expression of these
molecules has the potential to regulate antigen-presenting
function in plaque-associated microglia.
MATERIALS AND METHODS
In situ hybridization analysis
All animal husbandry and experimental protocols were IACUC
approved. APP23 transgenic mice express the human familial
AD mutant APP751 with Swedish double mutations at posi-
tions 670/671 (APPK670N, M671L) (Sturchler-Pierrat et al.,
1997). The expression of human APPsw is driven by the murine
Thy-1 promoter and is restricted to neurons. Unmanipulated
C57Bl/6 APP23 transgenic and C57Bl/6 wild-type mice were
anaesthesized by halothane inhalation and subjected to
intracardiac perfusion with a 4% PFA (paraformaldehyde)
saline solution at the ages indicated in the Results section and
the Figure legends. Brains were immediately harvested, post-
fixed in a series of 4% PFA sucrose solutions as described
previously prior to cryosectioning (Carson et al., 1993). In situ
hybridization was performed on free-floating cryosections as
described previously (Thrash et al., 2009). Briefly, coronal
sections (25 mm thick) were hybridized at 55˚C for 16 h with a
35S-labelled riboprobe (10
7 c.p.m./ml). Excess probe was
removed by washing at room temperature (23˚C) for 30 min
in 0.03 M NaCl, 0.003M sodium citrate (26SSC)containing 10
mM 2-mercaptoethanol, followed by a 1 h incubation with 4
mg/ml ribonuclease, 0.5 M NaCl, 0.5 M EDTA, 0.05 M Tris/HCl
(pH 7.5), at 37˚C. Sections were then washed under high-
stringency conditions for 1.5 h at 55˚C in 0.56SSC, 50%
formamide and 10 mM 2-mercaptoethanol, followed by a 1 h
incubation at 68˚C in 0.16SSC, 5 mM 2-mercaptoethanol and
0.1% N-lauryl sarcosine. Myeloid cells and blood vessels were
identified by their ability to bind biotinylated tomato lectin
(Sigma), whereas neuronal nuclei were identified by labelling
with biotinylated NeuN (Sigma). Bound biotinylated tomato
lectin or NeuN was visualized by standard strepavidin–
horseradish peroxidase methodology. To co-localize TREM2
expression with compact parenchymal Ab (amyloid b-peptide)
deposits and cerebral amyloid angiopathy, some brain sections
were stained with Thio-S (thioflavine-S). Sections were
mounted on to FisherBrand SuperFrost/plus slides (Fischer
Scientific) and dehydrated with ethanol and chloroform. Slides
were exposed for 3 days to Kodak X-AR film and dipped in
Ilford K-5 emulsion (Polysciences). After 3 weeks, slides were
developed with Kodak D19 developer (Fischer Scientific), fixed
and counterstained with Mayer’s haematoxylin.
Preparation of mixed glial cultures
Mixed glial cultures were prepared as described previously
(Carson et al., 1998, 1999). Briefly, brains from post-natal day
1–3 C57Bl/6 mice were stripped of meninges, and the cortices
mechanically dissociated, seeded into six-well plates and
maintained in DMEM (Dulbecco’s modified Eagle’s medium),
supplemented with 10% FBS (fetal bovine serum) and insulin
(5 mg/ml). After 2 weeks in vitro, cultures were maintained
in serum-free DMEM-based OM-7 medium for 2 days (Carson
et al., 1998). After 2 days in serum-free medium, cultures
were treated with TNF (tumour necrosis factor) (50 ng/ml),
Ab-(1–42) (25 mM) or TNF and Ab for 5 days. Cultures were
then dissociated into single-cell suspensions and microglial
activation was assayed by flow cytometry as described
previously (Carson et al., 1998, 1999).
Generation of TREM2 cell lines
Murine C57Bl/6 BV-2 microglial cells were transformed with
various amounts of WT-TREM-2 (WT is wild-type) or sh-
TREM2 (sh is short hairpin) lentiviral vectors in DMEM plus
Polybrene (2 mg/ml) and gently spun for 1.5 h at 4˚C. At 2
days post-infection, GFP
+ (green fluorescent protein) cells
were purified using a FACSAria cell sorter (BD Biosciences).
GFP
+ cell lines were derived from single-cell cultures. The
relative surface level of TREM2 expression in each cell line was
Dual induction of TREM2 and Tmem176b
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159determined using flow cytometry using a monoclonal anti-
TREM2 antibody (R&D Systems) and compared with TREM2
levels in untreated BV-2 cells.
qPCR (quantitative PCR) analysis of TREM2
expression levels
To quantify TREM2 mRNA expression, cDNA templates were
prepared from each cloned TREM2 BV-2 cell line as described
previously (Schmid et al., 2009). qPCR analysis of TREM2
expression was performed as described previously with primer
sets previously detailed in Schmid et al. (2009). In brief, a
constant amount of 200 ng of cDNA from each RT (reverse
transcription) or each dilution of the appropriate standard,
was amplified in 25 ml of TaqMan PCR Core Reagent (Applied
Biosystems) according to the manufacturer’s instructions. The
reaction mixture consisted of 0.5 unit of AmpliTaq Gold
polymerase, each of the four dNTPs (0.2 mM), with dUTP
replacing dTTP, each pair of primers (300 nM) and MgCl2
(3 mM final concentration) in the above-described Tris buffer.
Amplifications were performed in an ABI Prism 7700
Sequence Detector System (Applied Biosystems). Each sample
was analysed in duplicate. At the end of each experiment,
amplification products were fractionated by gel electrophor-
esis to verify that they migrated as a single band with the
expected size. Data were normalized to the endogenous
reference HPRT (hypoxanthine phosphoribosyl transferase);
then, using the Ct (comparative cycle threshold) method, the
amount of RNA transcripts were expressed as a reference to a
standardized unstimulated microglia sample. CT was defined
as low as transcripts were abundant. For validation of the
DDCt method, we also used standards for calibration of HPRT
and TREM2 cDNA as described previously (Schmid et al.,
2009). Using the standard curve, it was verified that the
absolute copy number of HPRT transcripts was of the same
order of magnitude in all samples analysed by qPCR.
Amyloid phagocytosis assay
HiLyteFluor
TM 647 (Anaspec)–Ab-(1–40) was resuspended in
Tris/EDTA (pH 8.2) at 20 mM and then incubated in the dark
for 3 days at 37˚C to promote aggregation. Microglial cells
were pretreated in low serum (0.5% FBS supplemented
with insulin) ¡LPS (50 ng/ml), ¡IFNc (100 units/ml) for 24 h
prior to the addition of aggregated fluorescently labelled Ab.
Amyloid phagocytosis and surface expression of TREM2 were
determined by flow-cytometric analysis 5 h post-addition of
100 nM aggregated HiLyteFluor
TM 647–Ab-(1–40).
Mixed lymphocyte proliferation assays
Naı ¨ve CD4
+ T-cells were isolated from lymph nodes harvested
from 6–8-week-old BALB/c mice and C57Bl/6 mice bred at
the UC Riverside vivarium as described previously (Carson
et al., 1998, 1999). In brief, CD3
+ T-cells were positively
enriched from single-cell lymph node suspensions using
antibody (anti-CD3)-conjugated magnetic beads. CD8
+ T-cells
were subsequently depleted from these suspensions using
anti-CD8-conjugated magnetic beads. Flow-cytometric ana-
lysis indicated .98% purity of the CD4
+ T-cell preparations.
T-cells were labelled with CFSE (carboxyfluorescein succini-
midyl ester) as described previously (Ploix et al., 2001). The
cloned GFP
+ BV-2 microglial cells lines were used as allo-
geneic antigen-presenting cells for BALB/C CD4
+ T-cells and
as syngeneic antigen-presenting cells for C57Bl/6 CD4
+ T-cells.
Following plating into 96-well tissue-culture plates, BV-2
+
cells were irradiated with 1500 rads. CFSE-labelled CD4
+ T-cells
were plated at a 1:4 ratio of antigen-presenting cells to CD4
+
T-cells. Following 5 days of co-culture, CD4
+ T-cells were
harvested and their CFSE levels were measured using a FACS
Calibur equipped with BD Cell Quest software (version 5.2.1).
CFSE data was quantified using FlowJo software (version 8.8.4;
Treestar).
Detection of secreted cytokines using flow
cytometric bead arrays
ProteinconcentrationsofIL(interleukin)-6,IL-10,CCL2[chemo-
kine C ligand 2; also called MCP1 (monocyte chemoattractant
protein-1)], IFN-c, TNF and IL-12p70 in the supernatants of
serum-free microglia/T cell co-cultures were measured using
the BD
TM CBA (cytokine bead array) mouse inflammation kit
according to the manufacturer’s protocol (BD Biosciences). In
brief, 500 ml of collected supernatants were incubated for 2 h
with 50 ml of mixed capture beads and 50 ml of the PE-
detection reagent. The PE-detection reagent is a mixture of
PE-conjugated anti-mouse IL-6, IL-10, CCL2, IFN-c, TNF and
IL-12p70 antibodies. The samples were washed and resus-
pended in 300 ml of wash buffer and analysed immediately by
flow cytometry using a BD FACSCalibur and BD Cell Quest
software (version 5.2.1). Cytokine protein concentrations were
determined using BD cytometric Bead Array Software
according to the instructions in the kit.
Scratch assay
The previously described cloned BV-2 cell lines were plated
and grown to confluency in serum-free medium. A linear
scratch was made in each confluent culture with a 0.6 cm
spatula tip and the cultures were returned to 37˚C for 6 h.
Quantification of the number of cells entering the scratch
zone was determined based on blinded analysis of digital
photographs. TREM2 mRNA expression was determined for
each culture analysed in each scratch assay.
Annexin V apoptosis assay of Tmem176b-
transfected cells
RAW 264.7 or BV2 cells were transfected using the cell line
nucleofector kit V according to the manufacturer’s instruc-
tions (Lonza Group). In brief, 1610
6 cells were incubated with
0.46 pmol of plasmid encoding CMV (cytomegalovirus)-driven
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(AcGFP–Tmem176b) and transfected using Amaxa program D-
032.Following transfection, cellswere incubatedfor24or 48h
and then harvested using commercially prepared cell dissoci-
ation buffer (Invitrogen). Cells were labelled with annexin V
according to the manufacturer’s instructions (BD Biosciences)
and levels of annexin V labelling on GFP
+ cells was quantified
using a BD FACSCalibur Flow equipped with BD Cell Quest
software (version 5.2.1).
RESULTS
Molecules associated with modulation of antigen
presentation are robustly up-regulated in
response to amyloid deposition
Previous reports have correlated increased expression of
TREM2 and Tmem176b with decreased autoimmune responses
(Louvet et al., 2005; Takahashi et al., 2005). In addition, we
previously reported that microglial expression of TREM2 was
highest in regions that are predisposed to develop amyloid
pathology (Schmid et al., 2002, 2009). Furthermore, Frank et al.
(2008) have reported that TREM2 immunoreactivity was
elevated in plaque-associated microglia in transgenic mice
with fully developed amyloid pathology. As yet the spatial
organization and kinetics of TREM2 expression in relation-
ship to aging, amyloid plaque formation and induction of
additional markers of microglia/macrophage activation are
unexamined. TREM2 is an orphan receptor that lacks an
intracellular signalling tail and is absolutely dependent on the
co-expression of DAP12 to mediate its intracellular signalling.
Therefore, inthe present study,weexaminedwhether increased
TREM2 expression paralleled plaque formation and was co-
incident with increased expression of DAP12 as well as Tmem176b
in APP23 transgenic mice (Figures 1–4). Finally, we also com-
pared the expression of these three molecules to the induced
expression of C1qA, a sensitive marker of general microglial
activation (Fa ¨rber et al., 2009).C1qA has also been identified as
being induced in plaque-associated microglia/macrophages,
as well as neurons (Korotzer et al., 1995; Afagh et al., 1996;
Lue et al., 2001; Fan and Tenner, 2004).
TREM2 can be expressed as a full-length receptor or a splice
variant lacking the transmembrane and intracellular domains
(Schmid et al., 2002; Piccio et al., 2008). Cell-associated TREM2
immunoreactivityhasthepotentialtoreflecteither cell-expressed
TREM2 or the binding of soluble TREM2 to ligand-expressing
cells. Therefore, in the present study, we measured mRNA ex-
pression. Figures 1 and 3 depict autoradiograms of sagittal
brain sections from age-matched WT and APP23 C57Bl/6 mice
hybridized with
33P-labelled ribroprobes. WT levels of TREM2
and DAP12 are not detected by autoradiogram analysis at all
Figure 1 TREM2 and DAP12 expression is induced co-ordinate with amyloid plaque deposition
Autoradiograms of sagittal brain sections from non-transgenic (A–C and G–I) and APP23 transgenic (D–F and J–L) age-matched
siblings. (A–F) Brain sections hybridized with
33P-labelled TREM2 riboprobes. (G–L) Brain sections hybridized with
33P-labelled
DAP12 riboprobes. Arrows indicated amyloid-associated induction of TREM2 and DAP12 expression.
Figure 2 Induced TREM2 expression surrounds Thio-S-positive plaques
(A and B) A brain section from a 10-month-old APP23 transgenic mouse. A
compact parenchymal plaque is visualized in green with Thio-S (A). TREM2
expression is visualized with a
33P-labelled ribroprobe (white grains in film
emulsion) (B).
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161ages examined (3, 6 and 16 months of age; Figures 1A–1C and
1G–1I) consistent with our previous reports (Schmid et al.,
2002; Thrash et al., 2009). In contrast, robust induction of both
TREM2 and DAP12 is readily detected in a punctate pattern of
expression in the cortex and hippocampus of APP23 mice. The
kinetics and spatial pattern of induction were identical for
both molecules (Figures 1D and 1E and 1J–1L). The appearance
of this pattern of expression was co-incident with the depo-
sition of amyloid plaques (Figure 2). Specifically, the detection
of Thio-S-positive plaques (Figure 2A) was always associated
with induced expression of TREM2 surrounding the plaque
(Figure 2B). The transmembrane adaptor molecule DAP12 has
the potential to mediate intracellular signalling for most of the
classic TREM family members. Therefore we tested whether
altered or increased expression of TREM1, TREM3 or TREM4
could be detected in APP23 transgenic mice as compared with
non-transgenic siblings. However, amyloid-associated induc-
tion of all other TREM family members was not detected (data
not shown).
C1q expression in the murine brain is known to increase
with age (Reichwald et al., 2009). Using in situ hybridization
analysis, we were also able to detect a reproducible global
increase in C1qA expression in murine brain sections that
was apparent by 16 months of age (Figures 3A–3C). As
previously reported, amyloid deposition was associated with
increased C1qA expression (Figures 3D–3E) (Pisalyaput and
Tenner, 2008; Reichwald et al. 2009). We observed a similar
global age-associated increase in Tmem176b expression in
Figure 3 C1qA and Tmem176b expression increases in WT mice with age and in association with amyloid plaque deposition in APP23
transgenic mice
Autoradiograms of sagittal brain sections from non-transgenic (A–C and G–I) and APP23 transgenic (D–F and J–L) age-matched
siblings. (A–F) Brain sections hybridized with
33P-labelled C1qA riboprobes. (G–L) Brain sections hybridized with
33P-labelled
Tmem176b riboprobes. Arrows indicated amyloid-associated induction of C1qA and Tmem176b expression.
Figure 4 Different zones of amyloid-associated microglial activation are defined by regional gene expression
(A–D) Brain sections from 16-month-old APP23 transgenic mice. Microglia, macrophages and blood vessels are visualized in brown
with tomato lectin. Nuclei are visualized in blue with haematoxylin. Expression of TREM2 (A), DAP12 (B), Tmem176b (C) and C1qA (D)
are visualized by
33P-labelled ribroprobes (black grains in film emulsion).
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age (Figures 3G–3L). Expression of Tmem176b in Purkinje
cells and cerebellar granule cells has also previously been
reported (Maeda et al., 2006). In the present study, we
observed an age-associated increase in Tmem176b expression
in Purkinje and cerebellar granule cells that was independent
of APP transgene expression. Tmem176 expression was also
elevated in a punctate pattern of expression similar to that
seen with C1qA riboprobes in the cortex and hippocampus of
APP23 transgenic mice (Figures 3J–3L).
Expression patterns of TREM2/DAP12,
Tmem176b and C1qA distinguish between
zone-specific and global amyloid-associated
activation of microglia
At the level of autoradiogram analysis all four molecules
(TREM2, DAP12, Tmem176b and C1qA) showed similar
amyloid-associated increases in expression (Figures 1 and 3).
However, differences in their patterns of expression were readily
detected when examined at the level of cell-type-specific
expression (Figures 4 and 5). In Figure 4, activated microglia
and macrophages can be detected surrounding amyloid pla-
ques. Strikingly, whereas expression of TREM2 (Figure 4A)
and DAP12 (Figure 4B) were robustly induced in subsets of
microglia on the outer zone of the plaques, Tmem176b
(Figure 4C) was induced within the inner zone of amyloid
plaques. C1qA (Figure 4D) served as a positive control
demonstrating that all microglia in the region of amyloid
plaques were activated and displayed elevated expression of
C1qA. In Figure 5, right-pointing arrows indicate plaque-
associatedmicroglia that express eitherTREM2(Figures 5A and
5B) or Tmem176b (Figures 5C and 5D), whereas left-pointing
arrows indicate plaque-associated TREM2
2 or Tmem176b
2
microglia. Although amyloid plaque deposition was always
associated with increased TREM2 expression (Figure 2), the
ratio of TREM2
+ to TREM2
2 microglia in the outer zone of the
plaque varied widely between animals. This same pattern of
amyloid-associated TREM2, DAP12 and Tmem176b expression
was also observed in all other APP and APP/PS1 transgenic
mouse models examined (data not shown).
TREM2 ligand-binding activity is up-regulated in
areas with amyloid plaque deposition
Several potential ligands have been reported for TREM2 that
differ dramatically in their structures (Klesney-Tait et al.,
2006). In addition, it is still unclear how many types of ligands
can trigger TREM2-mediated activation and whatisthe identity
of endogenous ligands expressed in the CNS. The unknown
Figure 5 TREM2 and Tmem176b are expressed by plaque-associated microglia in the outer and inner zones respectively of the amyloid
plaque
(A–D) Brain sections from 16-month-old APP23 transgenic mice. Microglia, macrophages and blood vessels are visualized in brown
with tomato lectin. Nuclei are visualized in blue with haematoxylin. Expression of TREM2 (A and B) and Tmem176b (C and D) are
visualized by
33P-labelled ribroprobes (black grains in film emulsion). (A and C) The focus at the level of the tomato lectin labelling. (B
and D) The focus at the level of the film emulsion. Left-pointing arrows indicate examples of tomato-lectin-positive cells negative for
riboprobe labelling. Right-pointing arrows indicate examples of tomato-lectin-positive cells positive for riboprobe labelling.
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163identity of CNS-expressed TREM2 ligand(s) precludes direct
analysis of co-ordinate induction of TREM2 and its ligand(s).
However, we and others have used a fusion protein composed
of the extracellular domain of TREM2 fused to the Fc region of
human IgG to detect TREM2 binding activity as an assay of
putative TREM2 ligand(s) expression (Hamerman et al., 2006).
TREM2 binding activity was detected in multiple cells in the
region immediately surrounding amyloid plaques (Figures 6A
and 6B). Although TREM2 binding activity can be detected on
macrophages (Hamerman et al., 2006) and microglia (DS Davis
and MJ Carson, unpublished data) by flow cytometry, TREM2
binding activity by IbaI
+ microglia was only rarely detected by
immunofluorescence in tissue sections (Figures 6C and 6E).
However,therobustinductionofTREM2bindingactivity inthe
same regions expressing high levels of TREM2 suggests that
TREM2 may regulate activation of microglia surrounding
amyloid plaques (Figures 4 and 6D).
To test whether Ab stimulated TREM2 expression directly,
isolated primary microglia and BV-2 microglial cells were
treated with aggregated amyloid for 24 h or 5 days. Flow-
cytometric and qPCR analysis failed to detect Ab-induced
increases in microglial expression of TREM2 (data not shown).
However, addition of aggregated amyloid for 5 days to mixed
glial cultures comprised of astrocytes, oligodendrocytes and
microglia did result in increased expression of TREM2 that
was comparable with the induction caused by TNF after 5
days of treatment (Figure 7A). Treating mixed glial cultures
with both amyloid and TNF did not increase microglial
expression of TREM2 more highly than that seen in cultures
treated with amyloid only (Figure 7A).
Increasing TREM2 expression promotes amyloid
phagocytois in unstimulated cells
To test the consequences of increasing TREM2 expression, we
used previously described overexpression and knock-down
vectors to modulate TREM2 expression in BV-2 microglial cells
(Takahashi et al., 2005). BV-2 cells were used because homo-
geneous cloned cell lines derived from single cells could be
generated and maintained following transduction with over-
expression and knock-down vectors. TREM2 has previously
been reported to promote phagocyosis of apoptotic cell debris,
selected classes of pathogenic bacteria, but not zymosan
particles derived from the walls of Sacchoarmyces cerevisiae,
Candida albicans or other types of particulate beads (Takahashi
et al., 2005; N9Diaye et al., 2009). Therefore, using these cloned
Figure 6 TREM2 binding activity is detected in the region of amyloid plaque deposition TREM2 expression is induced by aggregated
amyloid and promotes amyloid phagocytosis
TREM2–IgG fusion protein labelling of APP23 brain sections is visualized in brown by DAB (diaminobenzidine) immunohistochemistry
(A) and by immunofluorescence in red (D and E). Microglia and macrophages are visualized by immunofluorescence with Iba1 in
green (C and E). In (A and B) nuclei are visualized in blue with haematoxylin. (B) The absence of immunolabelling with secondary
antibodies directed against human IgG. (E) The merged images of (C and D).
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TREM2 expression would correlate positively with amyloid
phagocytosis (Figure 7B). We found that increasing TREM2
expression was tightly correlated (r
250.92) with phagocytosis
of Ab-(1–40) in a 5 h phagocytosis assay using unstimulated
BV-2 cell lines (green line, Figure 7B). Previous studies
examining TREM2-triggered phagocytosis had not examined
whether prior cell activation altered the propensity of TREM2
to regulate microglial phagocytosis. Therefore we also
examined Ab phagocytosis following a 24 h stimulation with
LPS(redline,Figure7B)orIFNc(blueline,Figure7B).Strikingly,
whereas IFNc did not alter the correlation between increasing
TREM2 expression and increasing Ab phagocytosis (r
250.92),
treating cells with LPS did. LPS alone is a potent stimulant of
amyloid phagocytosis. Adding aggregated Ab after 24 h of LPS
pre-treatment dramatically decreased the correlation between
TREM2 expression and phagocytosis (r
250.49).
TREM2 expression is associated with decreased
motility
TREM2 deficiency in humans is associated with alterations in
the expression of multiple cytoskeletal molecules (Kiialainen
et al., 2007). We therefore tested whether modulating TREM2
expression would alter cell motility in standard scratch assays
(Figure 8). In this assay, a uniform scratch is made in con-
fluent cultures of BV-2 microglial cells. Within 6 h, WT BV-2
cells can be detected migrating into the ‘scratch wound’.
Figure 8 represent examples of migration observed in the
BV-2 cells with the highest and lowest TREM2 levels. Using
cloned BV-2 microglial cell lines, we found that increasing
TREM2 levels was associated with a decrease in the number
of cells found within the scratch zone 6 h post-scratch
(Figures 8A and 8B). By contrast decreasing TREM2 expression
correlated with increased numbers of BV-2 cells within in the
scratch zone (Figures 8A and 8B).
TREM2 expression correlates with increased
antigen-presenting cell function as assayed by
T-cell proliferation and cytokine production
TREM2-mediated activation was initially described to increase
the expression of molecules required for antigen-presentation
toCD4
+T-cells (Bouchon et al.,2001).However, as yet, nodirect
examination of TREM2-regulated antigen-presenting cell
activity has been reported. In the present study we compared
theabilityoftwoclonedBV-2celllinesthatdiffered,5-foldin
TREM2 expression to act as antigen-presenting cells to
allogeneic CFSE-labelled BALB/c CD4
+ T-cells. We used two
measures of microglial antigen presentation: stimulation of T-
cell proliferation and stimulation of T-cell cytokine production.
T-cell proliferation was quantified by flow-cytometric analysis
of CFSE level per cell. In Figures 9(A) and 9(B), representative
data from a single experiment is shown. In Figure 9(C) data
from six experimental replicates is quantified, demonstrating
the reproducibility of TREM2 modulation of microglial antigen-
presenting cell function. After 5 days, only 3.7% of CD4
+ T-cells
completed six or more rounds of cell division when stimulated
by allogeneic TREM2lo BV-2 cells (Figure 9A). By contrast,
nearly37%ofCD4
+T-cellsunderwentsixormoreroundsofcell
division when stimulated by allogeneic TREM2hi BV-2 micro-
glial cells. When assaying cytokine and chemokine production
in the supernatants of BV-2 microglial-CD4
+ T-cell cultures, we
could not detect expression of IL-12, IFNc, IL-6 or the anti-
inflammatory cytokine IL-10 in T-cell cultures stimulated with
either TREM2lo or TREM2hi BV-2 microglial cells. By contrast,
both TNF and CCL2 were readily detected in T-cells stimulated
with either allogeneic TREM2lo and TREM2hi BV-2 microglial
cells. However, ,4-fold higher levels of TNF and CCL2 were
detected in T-cell cultures stimulated with allogeneic TREM2hi
BV-2 microglial cells. Taken together these data demonstrate
that higher levels of TREM2 correspond with greater antigen-
presenting cell function in microglia without triggering T-cell
production of IFNc. Increased TREM2 expression and increased
antigen-presenting cell function only loosely correlated with
increased MHC class II expression. TREM2hi cell lines displayed
,1.5-fold higher levels of MHC class II as quantified by flow-
cytometric analysis (data not shown).
Figure 7 TREM2 expression is induced by aggregated amyloid and promotes
amyloid phagocytosis
(A) Flow-cytometric analysis of TREM2 expression of the surface of CD11b
+
microglia in primary mixed glial cultures treated for 5 days with TNF only,
amyloid only or both TNF and amyloid. (B) Flow-cytometric analysis of cloned
BV-2 microglial cell lines phagocytosis of fluorescently labelled AB1-40 (mean
fluorescence intensity relative to WT BV-2 cells compared with TREM2 surface
expression) in untreated (green line), IFNc-treated (blue line) and LPS-treated
(red) cell lines. APC (allophycocyanin)-labelled TREM2 antibodies were used to
quantify the level of TREM2 expression in amyloid-treated BV-2 cell lines.
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165Tmem176b overexpression promotes cell death
Transfection of Tmem176b into immature antigen-presenting
cells prevents their differentiation into mature potent
antigen-presenting cells. Therefore we wished to repeat the
T-cell proliferation assays with Tmem176b-overexpression
cloned cell lines. However, we were unable to generate
Tmem176b cell lines with stable Tmem176b overexpression.
We therefore analysed the effect of Tmem176b on cell death
using annexin V labelling. We observed a nearly 40% in-
creased rate of cell death as judged by increased annexin V
labelling 48 h following transfection of either RAW macro-
phage (Figure 10A) and BV-2 microglial (Figure 10B) cells
with Tmem176b overexpression vectors as compared with
cells transfected with GFP-only overexpression vectors.
Transfecting BV-2 microglial and RAW macrophage cells with
a Tmem176b-overexpression vector had no effect on amyloid
phagocytosis (data not shown).
DISCUSSION
Microglial activation associated with amyloid plaque depos-
ition is a well-recognized feature of Alzheimer’s disease and
of amyloid pathogenesis in transgenic mouse models (Schwab
et al., 2009; Cameron and Landreth, 2010; Graeber and Streit,
2010). Repetitive two-photon imaging reveals that microglia
quickly recognize and accumulate around Ab aggregates.
However, the consequences of amyloid-associated microglial
activation are under substantial debate. Notably, the accu-
mulation of Ab is associated with insufficient or dysregulated
microglial phagocytic activity (Schwab et al., 2009; Cameron
and Landreth, 2010; Graeber and Streit, 2010). In addition,
microglial production of pro-inflammatory cytotoxic mole-
cules is suggested to play at least a partial role in neuronal
dysfunction. Indeed, two-photon imaging of amyloid trans-
genic mice has revealed active microglial interactions with
neurons in areas with detectable neuronal loss (Fuhrmann
et al., 2010). Although microglial expression of CX3CR1 has
been linked with limiting microglial neurotoxicity in a wide
array of neurodegenerative models, deletion of CX3CR1 reduced
neuronal loss in amyloid transgenic mice (Cardona et al., 2006;
Fuhrmann et al., 2010). These studies suggest that microglia
detrimentally contribute to amyloid pathogenesis. By contrast,
other studies have raised doubts as to the functional sig-
nificance of microglial activation in the disease process. For
example, no changes in amyloid pathogenesis were detected
following acute genetic [HSVTK (herpes simplex virus thymidine
kinase)] triggered ablation of large portions of proliferating
microglia (Grathwohl et al., 2009).
In many studies, all microglia/macrophages are analysed as
a single population. However, studies using bone marrow
chimaeric mice to genetically manipulate peripheral macrophages
Figure 8 TREM2 expression negatively correlates with cell motility
The number of cells within the scratch zone was quantified as a function of TREM2 expression per culture 6 h post-injury. (A)
Representative migration in scratched confluent TREM2lo (left-hand side) and TREM2hi (right-hand side) cultures. (B) Number of
cells per scratch zone as a function of TREM2 mRNA of each scratch-tested culture. The Pearson correlation co-efficient was used to
determine significance.
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these two types of macrophages are not functionally identical
(reviewed in Carson et al., 2006). Specifically, several groups
have reported that CCR2
+ CNS-infiltrating macrophages have
greater Ab phagocytic ability than CNS-resident microglia (El
Khoury et al., 2007; Yong and Rivest, 2009). Our present study
reveals additional heterogeneity in the macrophage populations
that define specific activation zones associated with amyloid
plaques in APP23 mice. While C1qA expression was detected in
all plaque-associated myeloid cells, Tmem176b expression was
mostprominentincellsintheinnerzoneofplaques.Bycontrast,
TREM2 was most prominently induced in cells on the outer
zones of the plaques.
The mechanisms driving this highly localized expression of
TREM2 and Tmem176b are as yet undefined. However, our data
implicate glia and neurons as playing critical regulatory roles.
Addition of aggregated Ab to primary microglia and BV-2 cells
failed to increase expression of TREM2 or Tmem176b (data not
shown). However, microglial expression of TREM2 was increased
when microglia were exposed to Ab i nt h ep r e s e n c eo ft h e
multiple cell types present in standard mixed glial cultures. By
contrast, microglial expression of Tmem176b did not change
with this treatment, perhaps because microglial expression of
Tmem176b is already very high in mixed glial culture microglia.
We speculate that in mixed glial cultures, the high levels of
Tmem176b expression may play a role in maintaining the
constant percentage of microglia observed in mature mixed glial
cultures (Carson et al., 1998). High Tmem176b expression may
limit microglia from increasing as a percentage of cells in culture,
even though these cells are continually proliferating by pro-
m o t i n gm i c r o g l i a lc e l ld e a t h .
Expression of a receptor does not necessarilyindicate that a cell
is constitutively activated by that receptor. However, in our
transgenic model, the expressiono fD A P 1 2 ,t h ea d a p t o rm o l e c u l e
mediating TREM2 intracellular signalling, and TREM2 binding
activity were bothdetected in the same plaque-associated regions
as TREM2 expression. In addition, flow-cytometric analysis reveal
that macrophages and microglia constitutively express TREM2
binding activity (Hamerman et al., 2006). Therefore TREM2 ex-
pression probably leads to TREM2-mediated activation.
Our in vitro assays suggest that this differential expression
will have functional consequences for processes relevant to
disease progression. For example, our data suggest that
TREM2/DAP12hi cells are less likely to migrate away from
plaques owing to lower motility. The robust phagocytic-
inducing properties of LPS by-passes or reduces the ability of
Figure 9 TREM2 expression positively correlates with antigen presentation
Cloned BV-2 microglial cell lines with ,10-fold difference in TREM2 RNA expression were used to stimulate the proliferation of
allogeneic (BALB/c) CFSE-labelled CD4
+ T-cells. Representative flow-cytometric analysis of T-cell proliferation using TREM2lo BV-2
cells or when using TREM2hi are depicted in (A) and (B) respectively. (C) The mean number of cells¡S.E.M. undergoing each round of
cell division in T-cells stimulated with TREM2lo (blue line) or TREM2hi (red line) BV-2 cells. (D) The levels of TNF and CCL2 found in
the supernatants of T-cell cultures stimulated with TREM2 lo (blue bars) or TREM2hi (red bars).
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167TREM2 to modulate Ab phagocytosis. Thus TREM2/DAP12hi
cells may only be more phagocytic than TREM2/DAP12hi cells
when in environments lacking other strong phagocytic stimuli,
such as those meditated by TLR4 (Toll-like receptor 4; the LPS
receptor). These data suggest that the relative importance
of TREM2-triggered phagocytosis may be less important for
amyloid clearance and more important for antigen capture
prior to antigen-presentation to CD4
+ T-cells. It is also possible
that other microglial-expressed DAP12-associated receptors,
such as SIRPB1, may play more prominent roles in regulating
Ab phagocytosis (Gaikwad et al., 2009). Our data would also
suggest that these other DAP12-associated functions would
also be limited to the subset of DAP12-expressing microglia
surrounding the outer zone of amyloid plaques.
T-cells are not generally hypothesized to play critical roles
in Alzheimer’s disease. However, the function of microglial
antigen-presentation has been hypothesized to differ from that
of the professional immune system (Byram et al., 2004; Carson
et al., 2006). Specifically, microglia are inefficient in promoting
or sustaining pro-inflammatory T-cell responses (Hickey and
Kimura, 1988; Carson et al., 1998, 1999). Thus microglia are
unlikely to play biologically significant roles in the initiation of
T-cell activation. Rather, after initial T-cell activation, T-cell
function is dependent on antigen-presentation within a tissue
to localize and direct T-cell responses. As demonstrated in a
model of facial axotomy, microglia are not only more effective
in driving neuroprotective T-cell responses than non-CNS
antigen-presenting cells, antigen presentation by microglia
can play absolutely essential roles in eliciting neuroprotection,
even in the presence of CNS-infiltrating peripheral antigen-
presenting cells (Davis and Carson, 2009).
TheroleofTREM2inpromotingneuroprotectiveresponsesis
suggested by three observations. First, in ongoing studies, we
have also observed induction of microglial expression of both
TREM2 and Tmem176b in the facial axotomy model at times
co-incident with the generation of neuroprotective T-cell
responses (data not shown and DS Davis and MJ Carson,
unpublished data). Secondly, blocking TREM2 function during
EAE increased the severity of EAE. Thirdly, introduction of
TREM2 into peripheral antigen-presenting cells promoted
morecompleteremissioninarelapsingremittingmodelofEAE.
Neuroprotective T-cell responses may also play roles in
more than neuronal survival. T-cells can limit TNF-induced
influx of neurotoxic macrophages into the CNS (Stalder et al.,
1998). More recently, several studies have demonstrated that
mice lacking T-cells have dramatically reduced performance
in learning and memory tasks (Brynskikh et al., 2008; Derecki
et al., 2010). Supplementation of lymphocytes to T-cell-
deficient mice improves performance in these assays. In vivo,
both TREM2 and Tmem176b expression have been correlated
with reduced pathology following autoimmune responses
(Louvet et al., 2005; Takahashi et al., 2007). Taken together
with the data presented in our present study, it is tempting to
speculate that, in amyloid pathology, Tmem176b may
promote death of activated macrophages, whereas TREM2-
triggered microglial antigen-presentation to CD4
+ T-cells may
provide neuroprotection, albeit insufficiently. However, this
same type of microglial activation may interfere with the
effectiveness of active immunization therapies designed to
elicit pro-inflammatory CD4
+ T-helper responses against
plaque-associated molecules. Alternatively, plaque-associated
activation of microglia may elicit T-cell-mediated neuropro-
tection and ‘wound repair responses’ that help maintain
optimal CNS function during immune therapies with pro-
inflammatory consequences (Fisher et al., 2010). Relevant to
this last speculation is the observation that epithelial repair in
a stem-cell-dependent model of colonic injury/repair was in-
complete and associated with an increase in pro-inflammatory
macrophages in TREM2-KO mice (Seno et al., 2009). Future
studies using TREM2 and Tmem176b KO and overexpression
models should help define whether specific forms of plaque-
associated microglial activation should be promoted to provide
neuroprotection during immune therapies.
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Figure 10 Tmem176b overexpression promotes annexin V labelling
RAW macrophage (A) and BV-2 microglial (B) cell lines were transiently
transfected with Tmem176b–GFP overexpression or GFP-only overexpression
plasmids. Annexin V labelling of GFP
+ cells was determined 48 h post-
transfection using flow-cytometric analysis (means¡S.E.M. for three
replicate experiments). Between replicate experiments, the final total cell
death ranged from ,35 to ,50% of cultured cells. Significance was
determined using the Student’s t test.
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